19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells

N/A

Report date: 2023/11/16 17:36:20

Base Information

Drug Name19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells
Drug Alias Name19(T2)28z1xx CAR T cells19(T2)28z1xx CAR-T cell therapyCD19-targeted 19(T2)28z1xx CAR-T cell therapyTAK-940
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaCentral Nervous System LymphomaWaldenstrom Macroglobulinemia +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co LtdMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaCentral Nervous System LymphomaWaldenstrom Macroglobulinemia +[10] 
Inactive IndicationsLymphomaLeukemiaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A